|
With
strong market demand for novel and effective wound healing products, TRT aims at securing a revenue-earning
licensing agreement, based on its lead compound, with a pharmaceutical or biotechnological companies at
the end of early Phase II clinical trials. TRT is actively searching for investors and partners in order to get to this stage. Based on comparable transactions the company
believes it has a high likelihood of achieving an out-licensing deal of significant value within 5 years.
Diabetic foot ulcers are not the only type of
pathology associated with wound healing. Impaired wound healing is commonly present in the elderly and
individuals suffering from neuropathy and /or poor circulation. It is estimated the healthcare costs of
diabetic chronic wounds (£700m-£900m p.a. in the UK ) represents approximately
a third of the total cost of all chronic wounds. An additional burden of wound healing is the
problem of skin scarring, a $12 billion annual market in the USA.
Investment in TRT may be eligible for either SEIS or EIS tax relief
On
successful development of an effective treatment for diabetic foot ulcers, TRT
would look to expand the application of MSF based therapies to other conditions
in which wound healing is compromised. These include bedsores and other non-healing
wounds in the elderly, post-surgery impaired healing, burns, certain skin
conditions, prevention of scarring, etc.
The unique properties of MSF bioactives
further provide a rational basis for developing
future "pipe-line" novel therapeutic strategies. These may include, for example (i) next
generation of synthetic non-peptide mimetics, (ii) purpose-designed
bioengineered matrix scaffolds loaded with MSF bioactives, and (iii) novel
drugs targeting MSF-specific signal transduction.
Besides the wound healing market, TRT has
identified pipe-line developments
applicable to cancer and cardiovascular diseases, as well as veterinary
medicine.
enquiries
return to home page
|
